[go: up one dir, main page]

WO2002008244A3 - Peptides as ns3-serine protease inhibitors of hepatitis c virus - Google Patents

Peptides as ns3-serine protease inhibitors of hepatitis c virus Download PDF

Info

Publication number
WO2002008244A3
WO2002008244A3 PCT/US2001/022678 US0122678W WO0208244A3 WO 2002008244 A3 WO2002008244 A3 WO 2002008244A3 US 0122678 W US0122678 W US 0122678W WO 0208244 A3 WO0208244 A3 WO 0208244A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
peptides
virus
protease inhibitors
serine protease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/022678
Other languages
French (fr)
Other versions
WO2002008244A2 (en
Inventor
Anil K Saksena
Viyyoor Moopil Girijavallabhan
Raymond G Lovey
Edwin E Jao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Dendreon Pharmaceuticals LLC
Original Assignee
Schering Corp
Corvas International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22822095&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2002008244(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DE60141608T priority Critical patent/DE60141608D1/en
Priority to HU0401730A priority patent/HU229997B1/en
Priority to NZ523782A priority patent/NZ523782A/en
Priority to EP01954764A priority patent/EP1385870B1/en
Priority to AT01954764T priority patent/ATE461207T1/en
Priority to MXPA03000627A priority patent/MXPA03000627A/en
Priority to JP2002514149A priority patent/JP4298289B2/en
Priority to SI200130967T priority patent/SI1385870T1/en
Priority to CA2410662A priority patent/CA2410662C/en
Application filed by Schering Corp, Corvas International Inc filed Critical Schering Corp
Priority to AU2001276988A priority patent/AU2001276988B2/en
Priority to SK75-2003A priority patent/SK288064B6/en
Priority to HK04100762.2A priority patent/HK1058047B/en
Priority to IL15367001A priority patent/IL153670A0/en
Priority to KR1020037000784A priority patent/KR100904788B1/en
Priority to AU7698801A priority patent/AU7698801A/en
Priority to DK01954764.5T priority patent/DK1385870T3/en
Priority to BR0112540-0A priority patent/BR0112540A/en
Publication of WO2002008244A2 publication Critical patent/WO2002008244A2/en
Priority to IL153670A priority patent/IL153670A/en
Priority to NO20030272A priority patent/NO332329B1/en
Anticipated expiration legal-status Critical
Publication of WO2002008244A3 publication Critical patent/WO2002008244A3/en
Priority to LU91910C priority patent/LU91910I2/en
Priority to CY2011020C priority patent/CY2011020I2/en
Priority to DE201212000004 priority patent/DE122012000004I1/en
Priority to NO2013003C priority patent/NO2013003I2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
PCT/US2001/022678 2000-07-21 2001-07-19 Peptides as ns3-serine protease inhibitors of hepatitis c virus Ceased WO2002008244A2 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
BR0112540-0A BR0112540A (en) 2000-07-21 2001-07-19 Peptides as Hepatitis C Virus Ns-3-Serine Protease Inhibitors
HK04100762.2A HK1058047B (en) 2000-07-21 2001-07-19 Peptides as ns3-serine protease inhibitors of hepatitis c virus
NZ523782A NZ523782A (en) 2000-07-21 2001-07-19 Peptides as NS3-serine protease inhibitors of hepatitis C virus
EP01954764A EP1385870B1 (en) 2000-07-21 2001-07-19 Peptides as ns3-serine protease inhibitors of hepatitis c virus
KR1020037000784A KR100904788B1 (en) 2000-07-21 2001-07-19 Novel Peptides as Hepatic C Virus Inhibitors of Ns3-serine Protease
MXPA03000627A MXPA03000627A (en) 2000-07-21 2001-07-19 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus.
JP2002514149A JP4298289B2 (en) 2000-07-21 2001-07-19 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
SI200130967T SI1385870T1 (en) 2000-07-21 2001-07-19 Peptides as ns3-serine protease inhibitors of hepatitis c virus
CA2410662A CA2410662C (en) 2000-07-21 2001-07-19 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
HU0401730A HU229997B1 (en) 2000-07-21 2001-07-19 Peptides as ns3-serine protease inhibitors of hepatitis c virus
AU2001276988A AU2001276988B2 (en) 2000-07-21 2001-07-19 Peptides as NS3-serine protease inhibitors of hepatitis C virus
SK75-2003A SK288064B6 (en) 2000-07-21 2001-07-19 Peptide compounds, pharmaceutical compositions comprising them and their use
IL15367001A IL153670A0 (en) 2000-07-21 2001-07-19 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
DE60141608T DE60141608D1 (en) 2000-07-21 2001-07-19 PEPTIDES AS INHIBITORS OF THE NS3 SERINE PROTEASE OF HEPATITIS C VIRUS
AT01954764T ATE461207T1 (en) 2000-07-21 2001-07-19 PEPTIDES AS INHIBITORS OF THE NS3 SERINE PROTEASE OF THE HEPATITIS C VIRUS
AU7698801A AU7698801A (en) 2000-07-21 2001-07-19 Novel peptides as NS3-serine protease inhibitors of hepatitis c virus
DK01954764.5T DK1385870T3 (en) 2000-07-21 2001-07-19 Peptides as inhibitors of NS3 serine protease from hepatitis C virus
IL153670A IL153670A (en) 2000-07-21 2002-12-25 Peptides as ns3-serine protease inhibitors of hepatitis c virus
NO20030272A NO332329B1 (en) 2000-07-21 2003-01-20 Compounds such as NS3 serine protease inhibitors for hepatitis C virus, pharmaceutical preparations and use of the compounds for the manufacture of a drug.
LU91910C LU91910I2 (en) 2000-07-21 2011-12-02 Boceprevir - Victrelis
CY2011020C CY2011020I2 (en) 2000-07-21 2011-12-16 NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS
DE201212000004 DE122012000004I1 (en) 2000-07-21 2012-01-13 Peptides as inhibitors of the hepatitis C virus NS3 serine protease.
NO2013003C NO2013003I2 (en) 2000-07-21 2013-02-12 Compounds as NS3 serine protease inhibitors for hepatitis C virus, pharmaceutical preparations and use of the compounds in the manufacture of a medicament

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22010800P 2000-07-21 2000-07-21
US60/220,108 2000-07-21

Publications (2)

Publication Number Publication Date
WO2002008244A2 WO2002008244A2 (en) 2002-01-31
WO2002008244A3 true WO2002008244A3 (en) 2003-06-19

Family

ID=22822095

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/022678 Ceased WO2002008244A2 (en) 2000-07-21 2001-07-19 Peptides as ns3-serine protease inhibitors of hepatitis c virus

Country Status (31)

Country Link
US (4) US7012066B2 (en)
EP (1) EP1385870B1 (en)
JP (3) JP4298289B2 (en)
KR (2) KR100904788B1 (en)
CN (3) CN1498224A (en)
AR (2) AR033985A1 (en)
AT (1) ATE461207T1 (en)
AU (2) AU2001276988B2 (en)
BR (1) BR0112540A (en)
CA (1) CA2410662C (en)
CY (2) CY1112267T1 (en)
CZ (1) CZ303213B6 (en)
DE (2) DE60141608D1 (en)
DK (1) DK1385870T3 (en)
EC (1) ECSP034438A (en)
ES (1) ES2341534T3 (en)
HU (1) HU229997B1 (en)
IL (2) IL153670A0 (en)
LU (1) LU91910I2 (en)
MX (1) MXPA03000627A (en)
MY (2) MY143322A (en)
NO (2) NO332329B1 (en)
NZ (1) NZ523782A (en)
PL (1) PL206255B1 (en)
PT (1) PT1385870E (en)
RU (2) RU2355700C9 (en)
SI (1) SI1385870T1 (en)
SK (1) SK288064B6 (en)
TW (1) TWI324611B (en)
WO (1) WO2002008244A2 (en)
ZA (1) ZA200210312B (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378422B2 (en) 2003-09-05 2008-05-27 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7427681B2 (en) 2000-12-21 2008-09-23 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7528142B2 (en) 2005-11-03 2009-05-05 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US7557106B2 (en) 2002-06-20 2009-07-07 Vertex Pharmaceuticals Incorporated Substituted pyrimidines useful as protein kinase inhibitors
US8187874B2 (en) 2003-10-27 2012-05-29 Vertex Pharmaceuticals Incorporated Drug discovery method
US11851422B2 (en) 2021-07-09 2023-12-26 Aligos Therapeutics, Inc. Anti-viral compounds

Families Citing this family (267)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0932617B1 (en) 1996-10-18 2002-01-16 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
PE20011350A1 (en) 2000-05-19 2002-01-15 Vertex Pharma PROPHARMAC OF AN INHIBITOR OF INTERLEUKIN-1ß CONVERTER ENZYME (ICE)
IL153670A0 (en) * 2000-07-21 2003-07-06 Schering Corp Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
SV2003000617A (en) 2000-08-31 2003-01-13 Lilly Co Eli INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1317450B1 (en) 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
GB2367816A (en) * 2000-10-09 2002-04-17 Bayer Ag Urea- and thiourea-containing derivatives of beta-amino acids
AU3659102A (en) * 2000-12-12 2002-06-24 Schering Corp Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
WO2003006490A1 (en) 2001-07-11 2003-01-23 Vertex Pharmaceuticals Incorporated Bridged bicyclic serine protease inhibitors
MXPA04003825A (en) 2001-10-24 2004-07-08 Vertex Pharma Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system.
MXPA04007163A (en) 2002-01-23 2004-10-29 Schering Corp Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection.
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7273885B2 (en) * 2002-04-11 2007-09-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
AU2011203054B2 (en) * 2003-04-11 2012-04-26 Vertex Pharmaceuticals, Incorporated Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease
AU2004230946A1 (en) * 2003-04-11 2004-10-28 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
CL2004001161A1 (en) 2003-05-21 2005-04-08 Boehringer Ingelheim Int COMPOUNDS DESCRIBES COMPOUNDS DERIVED FROM QUINOLINA; PHARMACEUTICAL COMPOSITION; AND ITS USE TO TREAT AN ILLNESS CAUSED BY THE HEPATITIS C VIRUS.
CA2526634C (en) * 2003-06-17 2012-09-18 Schering Corporation Process and intermediates for the preparation of 3-(amino)-3-cyclobutylmethyl-2-hydroxy-propionamide or salts thereof
JP4825129B2 (en) * 2003-06-17 2011-11-30 シェーリング コーポレイション Processes and intermediates for the preparation of (1R, 2S, 5S) -6,6-dimethyl-3-azabicyclo [3,1,0] hexane-2-carboxylate or salts thereof
AR044694A1 (en) 2003-06-17 2005-09-21 Schering Corp PROCESS AND INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF (1R, 2S, 5S) - 3 AZABICICLO [3,1,0] HEXANO-2- CARBOXAMIDE, N- [3- AMINO-1- (CYCLLOBUTILMETILE) - 2, 3 - DIOXOPROPIL] -3- [(2S) - 2 - [[[1,1- DIMETHYTILE] AMINO] CARBONYLAMINE] -3,3-DIMETHYL -1- OXOBUTIL] -6.6 DIMETHYL
CN102020700A (en) 2003-07-18 2011-04-20 沃泰克斯药物股份有限公司 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
JP4527722B2 (en) * 2003-08-26 2010-08-18 シェーリング コーポレイション Novel peptidomimetic NS3-serine protease inhibitor of hepatitis C virus
AU2004274468B2 (en) * 2003-09-18 2009-07-23 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
AU2004274051A1 (en) 2003-09-22 2005-03-31 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
EP1664092B1 (en) * 2003-09-26 2011-02-02 Schering Corporation Macrocyclic inhibitors of hepatitis c virus ns3 serine protease
TW200528472A (en) * 2003-10-10 2005-09-01 Vertex Pharma Inhibitors of serine proteases, particularly HCV ns3-ns4a protease
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
EP1678202B1 (en) 2003-10-27 2012-06-13 Vertex Pharmaceuticals Incorporated Hcv ns3-ns4a protease resistance mutants
CN1902216A (en) 2003-11-20 2007-01-24 先灵公司 Depeptidation inhibitor of hepatitis C virus NS3 protease
CN100509784C (en) * 2003-12-11 2009-07-08 先灵公司 Inhibitors of hepatitis C virus ns3/ns4a serine protease
WO2005070955A1 (en) 2004-01-21 2005-08-04 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
RS51243B (en) * 2004-01-30 2010-12-31 Medivir Ab. NS-3 SERINA HCV PROTEAZE INHIBITORS
EP1711515A2 (en) * 2004-02-04 2006-10-18 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
ES2322602T3 (en) 2004-02-24 2009-06-23 Japan Tobacco, Inc. CONDENSED HETEROTETHYCLIC COMPOUNDS AND ITS USE AS AN HCV POLYMERASE INHIBITOR.
US7635694B2 (en) 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
US7816326B2 (en) * 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
DK1730110T3 (en) * 2004-02-27 2010-09-27 Schering Corp Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
TW200529822A (en) * 2004-02-27 2005-09-16 Schering Corp Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus
CN1950393A (en) * 2004-02-27 2007-04-18 先灵公司 Novel inhibitors of hepatitis c virus ns3 protease
TW200602037A (en) * 2004-02-27 2006-01-16 Schering Corp Novel compounds as inhibitors of hepatitis C virus NS3 serine protease
EP1737821B1 (en) 2004-02-27 2009-08-05 Schering Corporation 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease
KR20060124729A (en) * 2004-02-27 2006-12-05 쉐링 코포레이션 Novel Compounds as Inhibitors of Hepatitis C Virus NS3 Serine Protease
CN1946690A (en) * 2004-02-27 2007-04-11 先灵公司 Cyclobutenedione groups-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
HUE024556T2 (en) * 2004-03-12 2016-02-29 Vertex Pharma Processes and intermediates for the preparation of aspartic acetal caspase inhibitors
PE20060309A1 (en) * 2004-05-06 2006-04-13 Schering Corp (1R, 2S, 5S) -N - [(1S) -3-AMINO-1- (CYCLOBUTYLMETHYL) -2,3-DIOXOPROPYL] -3 - [(2S) -2 [[[(1,1-DIMETHYLETHYL) AMINO] CARBONYL] AMINO] -3,3-DIMETHYL-1-OXOBUTIL] -6,6-DIMETHYL-3-AZABICYCLO [3.1.O] HEXAN-2-CARBOXAMIDE AS INHIBITOR OF NS3 / NS4A SERINE PROTEASE OF L VIRUS
ES2328596T3 (en) * 2004-05-20 2009-11-16 Schering Corporation PROLINES REPLACED AS INHIBITORS OF SERINA PROTEASA OF VIRUS NS3 OF HEPATITIS C.
UY29016A1 (en) 2004-07-20 2006-02-24 Boehringer Ingelheim Int ANALOGS OF INHIBITING DIPEPTIDES OF HEPATITIS C
CA2573346C (en) 2004-07-20 2011-09-20 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
JP2008511633A (en) 2004-08-27 2008-04-17 シェーリング コーポレイション Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease
ES2373450T3 (en) * 2004-10-01 2012-02-03 Scynexis, Inc. CYCLOSPORINE DERIVATIVES REPLACED WITH 3-Ether AND 3-THIOETHER FOR THE TREATMENT AND PREVENTION OF INFECTION WITH HEPATITIS C.
US7196161B2 (en) * 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
TW201300108A (en) 2004-10-01 2013-01-01 Vertex Pharma HCV NS3-NS4A protease inhibition
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
GB0426661D0 (en) * 2004-12-06 2005-01-05 Isis Innovation Pyrrolidine compounds
US20070021351A1 (en) * 2005-06-02 2007-01-25 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
CA2611155A1 (en) 2005-06-02 2006-12-07 Schering Corporation Pharmaceutical formulations and methods of treatment using the same
US20060276407A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
US20060275366A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
US20060281689A1 (en) * 2005-06-02 2006-12-14 Schering Corporation Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
US20060276406A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
WO2006130686A2 (en) 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors in combination with food
AU2006252623A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation useful for treating disorders associated with hepatitis C virus
US20060276405A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods for treating hepatitis C
TWI449711B (en) * 2005-06-30 2014-08-21 Virobay Inc Hcv inhibitors
US7608592B2 (en) * 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
EP2305695A3 (en) 2005-07-25 2011-07-27 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
BRPI0614696A2 (en) 2005-07-29 2011-04-12 Tibotec Pharm Ltd macrocyclic hepatitis c virus inhibitors
JP5230417B2 (en) 2005-07-29 2013-07-10 テイボテク・フアーマシユーチカルズ Macrocycle inhibitor of hepatitis C virus
AU2006275413B2 (en) * 2005-08-02 2012-07-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
DE602006013492D1 (en) 2005-08-19 2010-05-20 Vertex Pharma PROCEDURE AND INTERMEDIATE PRODUCTS
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (en) 2005-08-26 2007-08-22 Vertex Pharma INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS
JP5322647B2 (en) * 2005-09-30 2013-10-23 スシネキス インク Arylalkyl and heteroarylalkyl derivatives of cyclosporin A for the treatment and prevention of viral infections
WO2007041632A2 (en) * 2005-09-30 2007-04-12 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
US8119592B2 (en) * 2005-10-11 2012-02-21 Intermune, Inc. Compounds and methods for inhibiting hepatitis C viral replication
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
EP1951748B1 (en) 2005-11-11 2013-07-24 Vertex Pharmaceuticals, Inc. Hepatitis c virus variants
AR056805A1 (en) 2005-11-14 2007-10-24 Schering Corp AN OXIDATION PROCESS FOR THE PREPARATION OF N- (3- AMINO-1- (CICLOBUTILMETIL) -2,3- DIOXOPROPIL) -3- (N - ((TER-BUTILAMINO) CARBONIL) -3- METIL-L- VALIL) -6,6- DIMETIL-3- AZABICICLO (3.1.0) HEXANO -2- CARBOXAMIDE AND RALATED COMPOUNDS
MX2008008350A (en) * 2005-12-22 2008-09-03 Schering Corp Process for the preparation of 6, 6-dimethyl-3-azabicyclo-[3.1.0] -hexane compounds and enantiomeric salts thereof.
NZ569293A (en) 2005-12-23 2011-10-28 Zealand Pharma As Modified lysine-mimetic compounds
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
CL2007000361A1 (en) * 2006-02-09 2008-01-25 Wyeth Corp A combination comprising an inhibitor of the hepatitis c virus (vhc) arn polymerase and a vhc protease inhibitor; pharmaceutical composition that includes it; and use of the combination to treat disorders associated with vhc.
WO2007092616A2 (en) * 2006-02-09 2007-08-16 Schering Corporation Combinations comprising hcv protease inhibitor(s) and hcv polymerase inhibitor(s), and methods of treatment related thereto
US8039475B2 (en) 2006-02-27 2011-10-18 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
EP1998765A2 (en) * 2006-03-03 2008-12-10 Schering Corporation Pharmaceutical combinations of hcv-protease and -ires inhibitors
CA2645684A1 (en) * 2006-03-06 2007-09-13 Abbott Laboratories Compositions and methods of use of ritonavir for treating hcv
NZ571280A (en) 2006-03-16 2011-10-28 Vertex Pharma Deuterated hepatitis C protease inhibitors
US20080045530A1 (en) * 2006-04-11 2008-02-21 Trixi Brandl Organic Compounds and Their Uses
CN101421292A (en) * 2006-04-11 2009-04-29 诺瓦提斯公司 HCV inhibitors
US7825152B2 (en) * 2006-04-11 2010-11-02 Novartis Ag Organic compounds and their uses
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
US8420122B2 (en) * 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
CA2650395A1 (en) * 2006-04-28 2007-11-08 Schering Corporation Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
CN101495095B (en) * 2006-04-28 2013-05-29 默沙东公司 Process for Precipitating and Isolating 6,6-Dimethyl-3-aza-bicyclo[3.1.0]hexane-amide Compounds by Controlled Precipitation and Pharmaceutical Preparations Containing The Same
ES2361635T3 (en) 2006-05-19 2011-06-20 Scynexis, Inc. CYCLOSPORINS FOR THE TREATMENT AND PREVENTION OF EYE DISORDERS.
EP2019837B1 (en) * 2006-05-23 2011-03-23 Irm Llc Compounds and compositions as channel activating protease inhibitors
AU2007253819B2 (en) * 2006-05-23 2011-02-17 Irm Llc Compounds and compositions as channel activating protease inhibitors
KR101089112B1 (en) * 2006-06-02 2011-12-06 피씨 제스띠옹 에스.아.에스. Active electronic management
KR20090024834A (en) * 2006-07-05 2009-03-09 인터뮨, 인크. New Inhibitors of Hepatitis C Virus Replication
EP2049474B1 (en) 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
RU2009109355A (en) 2006-08-17 2010-09-27 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) OUTLET POLYMERASE INHIBITORS
US20080182895A1 (en) * 2006-08-25 2008-07-31 Howe Anita Y M Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto
RU2009113664A (en) * 2006-09-13 2010-10-20 Новартис АГ (CH) MACROCYCLIC INHIBITORS OF HCV AND THEIR APPLICATIONS
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
TW200831084A (en) * 2006-11-21 2008-08-01 Genelabs Tech Inc Anti-viral compounds
TW200827368A (en) * 2006-11-21 2008-07-01 Genelabs Tech Inc Amido anti-viral compounds
JP2010512317A (en) * 2006-12-07 2010-04-22 シェーリング コーポレイション pH sensitive matrix formulation
CA2672268A1 (en) * 2006-12-15 2008-06-26 Schering Corporation Bisulfite purification of an alpha-keto amide
CA2672620A1 (en) * 2006-12-20 2008-07-03 Schering Corporation Process for preparing (1r,2s,5s)-n-[(1s)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2s)-2-[[[(1,1-dimethylethyl)amino]-carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
DK2468724T3 (en) 2006-12-21 2016-02-22 Zealand Pharma As Synthesis of pyrrolidine compounds
WO2008082484A1 (en) 2006-12-22 2008-07-10 Schering Corporation 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections
WO2008082488A1 (en) * 2006-12-22 2008-07-10 Schering Corporation 4, 5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections
CN101611025A (en) 2006-12-22 2009-12-23 先灵公司 5,6-cyclized indole derivatives and methods of use thereof
US20080161254A1 (en) * 2007-01-03 2008-07-03 Virobay, Inc. Hcv inhibitors
CN101600428A (en) 2007-02-09 2009-12-09 Irm责任有限公司 Compounds and compositions as inhibitors of channel-activating proteases
AU2008219704A1 (en) 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR065498A1 (en) 2007-02-27 2009-06-10 Vertex Pharma VX-950 CO-CRITALS (A HEPATITIS C VIRUS INHIBITOR) AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND
CN101679240A (en) * 2007-03-23 2010-03-24 先灵公司 P1-non-epimerizable ketoamide inhibitors of HCV NS3 protease
BRPI0811020A2 (en) * 2007-05-03 2015-07-21 Intermune Inc Compound, pharmaceutical composition and methods of inhibiting ns3 / ns4 protease activity, treating hepatic fibrosis, enhancing liver function in an individual with hepatitis C infection and compounding methods, administering virus infection inhibitor hepatitis c (hcv) and oral dosage form distribution.
AU2008248116A1 (en) 2007-05-04 2008-11-13 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
CA2686546A1 (en) * 2007-05-10 2008-11-20 Intermune, Inc. Novel peptide inhibitors of hepatitis c virus replication
EP2188274A4 (en) 2007-08-03 2011-05-25 Boehringer Ingelheim Int Viral polymerase inhibitors
AU2008295484B2 (en) * 2007-08-29 2013-09-26 Merck Sharp & Dohme Llc Substituted indole derivatives and methods of use thereof
BRPI0816116A2 (en) * 2007-08-29 2015-03-03 Schering Corp 2,3-SUBSTITUTED INDOL DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS.
TW200911807A (en) * 2007-08-29 2009-03-16 Schering Corp 2,3-substituted azaindole derivatives and methods of use thereof
AU2008297015B2 (en) 2007-08-30 2013-08-22 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
ES2369321T3 (en) * 2007-09-14 2011-11-29 Schering Corporation PROCEDURE FOR THE TREATMENT OF PATIENTS WITH HEPATITIS C.
CA2702132A1 (en) * 2007-10-10 2009-04-16 Novartis Ag Spiropyrrolidines and their use against hcv and hiv infection
US8419332B2 (en) * 2007-10-19 2013-04-16 Atlas Bolt & Screw Company Llc Non-dimpling fastener
CN102317285A (en) * 2007-11-16 2012-01-11 先灵公司 Substituted indole derivatives of 3-amino-sulfonyl and method of use thereof
MX2010005356A (en) * 2007-11-16 2010-05-27 Schering Corp 3-heterocyclic substituted indole derivatives and methods of use thereof.
MX2010005809A (en) * 2007-11-28 2010-06-09 Schering Corp Dehydrohalogenation process for the preparation of intermediates useful in providing 6,6-dimethyl-3-azabicyclo-[3.1.0]-hexane compounds.
NZ585370A (en) 2007-12-19 2012-09-28 Boehringer Ingelheim Int Viral polymerase inhibitors
AR071270A1 (en) * 2007-12-21 2010-06-09 Schering Corp PROCESS FOR THE SYNTHESIS OF 3- AMINO-3 CYCLLOBUTILMETIL -2- HYDROXIPROPIONAMIDE AND USE OF THE SAME
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
BRPI0908021A2 (en) * 2008-02-04 2015-07-21 Idenix Pharmaceuticals Inc Compound, Pharmaceutical Composition, and, Uses of Compound or Pharmaceutical Composition
CA2720729A1 (en) * 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102046648A (en) 2008-05-29 2011-05-04 百时美施贵宝公司 Hepatitis c virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009148615A1 (en) * 2008-06-06 2009-12-10 Scynexis, Inc. Cyclosporin analogs and their use in the treatment of hcv infections
EP2280989B1 (en) * 2008-06-06 2016-02-10 Scynexis, Inc. Cyclosporin analogs and their use in the treatment of hcv infections
AR072088A1 (en) * 2008-06-13 2010-08-04 Schering Corp TRICYCLE INDOL DERIVATIVES AND THEIR METHODS OF USE
CN102816106A (en) 2008-06-24 2012-12-12 默沙东公司 Biocatalytic processes for the preparation of substantially stereomerically pure fused bicyclic proline compounds
US8188137B2 (en) 2008-08-15 2012-05-29 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
WO2010022125A1 (en) 2008-08-20 2010-02-25 Schering Corporation Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734489C (en) 2008-08-20 2016-11-08 Southern Research Institute Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2010022121A1 (en) 2008-08-20 2010-02-25 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8470834B2 (en) 2008-08-20 2013-06-25 Merck Sharp & Dohme Corp. AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20110075019A (en) * 2008-10-15 2011-07-05 인터뮨, 인크. Therapeutic Antiviral Peptides
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2009334790B2 (en) * 2008-12-31 2016-09-08 Scynexis, Inc. Derivatives of cyclosporin A
CN102271699A (en) 2009-01-07 2011-12-07 西尼克斯公司 Cyclosporine derivative for use in the treatment of HCV and HIV infection
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
US8102720B2 (en) * 2009-02-02 2012-01-24 Qualcomm Incorporated System and method of pulse generation
AR075584A1 (en) * 2009-02-27 2011-04-20 Intermune Inc THERAPEUTIC COMPOSITIONS THAT INCLUDE beta-D-2'-DESOXI-2'-FLUORO-2'-C-METHYLYCTIDINE AND A CARDIEX ISOINDOL ACID DERIVATIVE AND ITS USES. COMPOUND.
WO2010101967A2 (en) 2009-03-04 2010-09-10 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole hcv polymerase inhibitors
EP2417134B1 (en) 2009-04-08 2017-05-17 Idenix Pharmaceuticals LLC. Macrocyclic serine protease inhibitors
US20110182850A1 (en) * 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20120244122A1 (en) 2009-05-28 2012-09-27 Masse Craig E Peptides for the Treatment of HCV Infections
AU2010253791A1 (en) 2009-05-29 2011-11-24 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C
AR077139A1 (en) 2009-06-23 2011-08-03 Gilead Sciences Inc PHARMACEUTICAL COMPOSITIONS USEFUL TO TREAT VCH
US20110034469A1 (en) 2009-08-04 2011-02-10 Takeda Pharmaceutical Company Limited Heterocyclic Compound
CA2769652A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
US9156818B2 (en) 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
CA2775697A1 (en) * 2009-09-28 2011-03-31 Intermune, Inc. Cyclic peptide inhibitors of hepatitis c virus replication
WO2011041551A1 (en) * 2009-10-01 2011-04-07 Intermune, Inc. Therapeutic antiviral peptides
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
CA2782024A1 (en) 2009-11-25 2011-06-03 Schering Corporation Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
TW201136942A (en) 2009-12-18 2011-11-01 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
US9433621B2 (en) 2010-02-18 2016-09-06 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CN102844314B (en) * 2010-02-25 2015-05-20 基督教高等教育科学研究和病人护理协会 Preparation method of α-acyloxy β-formylaminoamide
ES2558554T3 (en) 2010-03-09 2016-02-05 Merck Sharp & Dohme Corp. Condensed tricyclic silyl compounds and methods of their use for the treatment of viral diseases
AU2011286276A1 (en) 2010-07-26 2013-01-24 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
WO2012050848A1 (en) 2010-09-29 2012-04-19 Schering Corporation Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
AR085352A1 (en) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc MACROCICLIC INHIBITORS OF SERINA PROTEASA, ITS PHARMACEUTICAL COMPOSITIONS AND ITS USE TO TREAT HCV INFECTIONS
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
WO2012142085A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013039876A1 (en) 2011-09-14 2013-03-21 Merck Sharp & Dohme Corp. Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
SG2014011670A (en) 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
SG2014011647A (en) 2011-10-21 2014-08-28 Abbvie Inc Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon.
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US20130123325A1 (en) 2011-11-14 2013-05-16 Sven Ruf Use of boceprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
WO2013178682A2 (en) * 2012-05-30 2013-12-05 Chemo Ibérica, S.A. Multicomponent process for the preparation of bicyclic compounds
CN103508918B (en) * 2012-06-18 2015-09-09 上海医药工业研究院 With the Alpha-hydroxy beta-amino ester compound and preparation method thereof of cyclobutyl
WO2014053533A1 (en) 2012-10-05 2014-04-10 Sanofi Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
WO2014061034A1 (en) * 2012-10-18 2014-04-24 Msn Laboratories Limited Process for preparation of boceprevir and intermediates thereof
SI2909205T1 (en) 2012-10-19 2017-02-28 Bristol-Myers Squibb Company 9-methyl substituted hexadecahydrocyclopropa(e)pyrrolo(1,2-a)(1,4)diazacyclopentadecinyl carbamate derivatives as non-structural 3 (ns3) protease inhibitors for the treatment of hepatitis c virus infections
JP2015536940A (en) 2012-10-29 2015-12-24 シプラ・リミテッド Antiviral phosphonate analogs and methods for their production
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014083575A2 (en) 2012-11-29 2014-06-05 Mylan Laboratories Ltd Improved process for the preparation of boceprevir intermediate
CN103936652B (en) * 2013-01-18 2016-07-06 上海医药工业研究院 Intermediate compound IV of anti-hepatitis C medicine Boceprevir and its preparation method and application
CN103936627B (en) * 2013-01-18 2016-08-31 上海医药工业研究院 Intermediate VII of anti-hepatitis medicine Boceprevir and its preparation method and application
CN103936818B (en) * 2013-01-18 2017-09-29 上海医药工业研究院 Anti- hepatitis medicine Boceprevir intermediate I and its preparation method and application
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2014240122B2 (en) 2013-03-14 2019-02-14 Onyx Therapeutics, Inc. Dipeptide and tripeptide epoxy ketone protease inhibitors
AR095426A1 (en) 2013-03-14 2015-10-14 Onyx Therapeutics Inc TRIPEPTIDE INHIBITORS OF PROTEASA EPOXYCETONE
EP2805705B1 (en) 2013-05-23 2016-11-09 IP Gesellschaft für Management mbH Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid
CN103387510B (en) * 2013-08-08 2015-09-09 苏州永健生物医药有限公司 A kind of synthetic method of β-amino-alpha-hydroxycyclobutylbutanamide hydrochloride
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
JP6466433B2 (en) * 2013-10-24 2019-02-06 ビーブ・ヘルスケア・ユーケイ・（ナンバー５）・リミテッドＶｉｉＶ Ｈｅａｌｔｈｃａｒｅ ＵＫ （Ｎｏ．５） Ｌｉｍｉｔｅｄ Inhibitors of human immunodeficiency virus replication
US10167298B2 (en) 2013-10-30 2019-01-01 Merck Sharp & Dohme Corp. Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
CN106810485A (en) * 2015-11-27 2017-06-09 上海现代制药股份有限公司 A kind of Preparation Method And Their Intermediate of chiral boxidine alkanone
JP7129703B2 (en) 2016-04-28 2022-09-02 エモリー ユニバーシティー Alkyne-Containing Nucleotide and Nucleoside Therapeutic Compositions and Uses Associated Therewith
WO2017222917A1 (en) * 2016-06-21 2017-12-28 Inception 4, Inc. Aliphatic prolinamide derivatives
JP7179721B2 (en) * 2016-06-21 2022-11-29 オリオン・オフサルモロジー・エルエルシー Heterocyclic prolinamide derivative
EP3472151A4 (en) 2016-06-21 2020-03-04 Orion Ophthalmology LLC CARBOCYCLIC PROLINAMIDE DERIVATIVES
WO2018073110A1 (en) 2016-10-20 2018-04-26 Basf Se Quinoline compounds as fungicides
EP3571190A1 (en) 2017-01-23 2019-11-27 Basf Se Fungicidal pyridine compounds
WO2018184882A1 (en) 2017-04-06 2018-10-11 Basf Se Pyridine compounds
ES2870106T3 (en) 2017-05-05 2021-10-26 Zealand Pharma As Modulators of gap junctional communication and their use for the treatment of diabetic eye disease
EP3927703B1 (en) 2019-02-19 2023-04-05 Univerza V Ljubljani Antibacterials based on monocyclic fragments coupled to aminopiperidine naphthyridine scaffold
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
EP4635972A3 (en) * 2020-07-20 2025-12-24 Enanta Pharmaceuticals, Inc. Functionalized peptides as antiviral agents
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
US11976084B2 (en) 2020-11-23 2024-05-07 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
ES2999271T3 (en) * 2021-04-16 2025-02-25 Fujian Akeylink Biotechnology Co Ltd Ring-modified proline short peptide compound and use thereof
WO2022235605A1 (en) 2021-05-04 2022-11-10 Enanta Pharmaceuticals, Inc. Novel macrocyclic antiviral agents
US12398147B2 (en) 2021-05-11 2025-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic spiropyrrolidine derived antiviral agents
US12479854B2 (en) 2021-07-29 2025-11-25 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023043816A1 (en) 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
US11912714B2 (en) 2021-11-12 2024-02-27 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11858945B2 (en) 2021-11-12 2024-01-02 Enanta Pharmaceuticals, Inc. Alkyne-containing antiviral agents
US11919910B2 (en) 2021-11-12 2024-03-05 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023107417A1 (en) 2021-12-08 2023-06-15 Enanta Pharmaceuticals, Inc. Heterocyclic antiviral agents
US11993600B2 (en) 2021-12-08 2024-05-28 Enanta Pharmaceuticals, Inc. Saturated spirocyclics as antiviral agents
CN114133350B (en) * 2021-12-16 2023-05-23 浙江乐普药业股份有限公司 Preparation method of anti-neocrown drug Paxlovid intermediate
WO2023149981A1 (en) * 2022-02-07 2023-08-10 Purdue Research Foundation Compounds for the treatment of sars
WO2023196307A1 (en) 2022-04-05 2023-10-12 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
CN114736151B (en) * 2022-04-13 2023-04-21 湖南复瑞生物医药技术有限责任公司 Preparation method of Pa Luo Weide key intermediate and structural formula of compound
CN115160205B (en) * 2022-07-08 2024-06-07 上海皓鸿生物医药科技有限公司 Method for preparing (S) -1- (tert-butoxycarbonyl) -2, 5-dihydro-1H-pyrrole-2-carboxylic acid and salt thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017679A1 (en) * 1996-10-18 1998-04-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
WO1999007734A2 (en) * 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
WO2000052032A1 (en) * 1999-03-03 2000-09-08 Dainippon Pharmaceutical Co., Ltd. Heterocyclic compounds, intermediates thereof and elastase inhibitors
WO2001040262A1 (en) * 1999-12-03 2001-06-07 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
WO2001074768A2 (en) * 2000-04-03 2001-10-11 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU177134B (en) * 1977-07-18 1981-07-28 Richter Gedeon Vegyeszet Process for preparing angiotensin ii analogues containing alpha-hydroxy-acid in position 1 with angiotensin ii antagonist activity
DE2936099A1 (en) * 1979-09-06 1981-04-02 Victor Dipl.- Chem. 8000 München Brantl PHARMACOLOGICALLY ACTIVE PEPTIDES
JPS5781447A (en) * 1980-11-11 1982-05-21 Toyo Jozo Co Ltd Human chorionic gonadotropic hormone c-terminal fragment
DE3481913D1 (en) * 1983-04-27 1990-05-17 Ici America Inc PROLIN DERIVATIVES.
US5496927A (en) * 1985-02-04 1996-03-05 Merrell Pharmaceuticals Inc. Peptidase inhibitors
CA1341029C (en) 1985-02-04 2000-06-20 Michael Kolb Peptidase inhibitors
CN1074422C (en) 1987-11-18 2001-11-07 希龙股份有限公司 Method for preparing isolated polypeptides containing HCV epitopes
ZA897514B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
DE69024378T2 (en) 1989-02-01 1996-09-12 Asahi Glass Co. Ltd., Tokio/Tokyo Azeotropic or azeotrope-like composition based on chlorofluorocarbons
US5359138A (en) * 1989-04-15 1994-10-25 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Poststatin and related compounds or salts thereof
US5162500A (en) * 1989-04-15 1992-11-10 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Poststatin and related compounds or salts thereof
CA2079105C (en) 1990-04-04 2000-06-13 Michael Houghton Hepatitis c virus protease
JP2804817B2 (en) 1990-04-13 1998-09-30 財団法人微生物化学研究会 Method for producing 3-amino-2-oxo fatty acid derivative
JPH04149166A (en) 1990-10-12 1992-05-22 Nippon Kayaku Co Ltd Novel keto acid amide derivative
CA2098609A1 (en) 1990-12-28 1992-06-29 Raymond T. Bartus Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
FR2686086A1 (en) * 1992-01-15 1993-07-16 Adir NOVEL THERAPEUTICALLY ACTIVE PEPTIDE AND PSEUDOPEPTIDE DERIVATIVES IN BLOOD COAGULATION CASCADE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.
WO1993015193A1 (en) * 1992-01-31 1993-08-05 Abbott Laboratories Mammalian expression systems for hcv proteins
AU4544993A (en) 1992-06-24 1994-01-24 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity
US5514694A (en) * 1992-09-21 1996-05-07 Georgia Tech Research Corp Peptidyl ketoamides
US5414018A (en) * 1993-09-24 1995-05-09 G. D. Searle & Co. Alkylaminoalkyl-terminated sulfide/sulfonyl-containing propargyl amino-diol compounds for treatment of hypertension
US5843450A (en) * 1994-02-14 1998-12-01 Abbott Laboratories Hepatitis GB Virus synthetic peptides and uses thereof
IT1272179B (en) * 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio METHODOLOGY TO REPRODUCE IN VITRO THE PROTEOLITHIC ACTIVITY OF THE NS3 PROTEASE OF THE VIRUS HCV.
US6285380B1 (en) * 1994-08-02 2001-09-04 New York University Method and system for scripting interactive animated actors
RU2104284C1 (en) * 1994-10-20 1998-02-10 Научно-исследовательский институт вирусологии им.Д.И.Ивановского РАМН Synthetic oligoypeptides specifically interacting with antibodies raised to hepatitis c virus, methods of diagnosis hcv-infection (variants)
US5843752A (en) * 1995-05-12 1998-12-01 Schering Corporation Soluble active hepatitis C virus protease
US5919765A (en) 1995-06-07 1999-07-06 Cor Therapeutics, Inc. Inhibitors of factor XA
GB9517022D0 (en) 1995-08-19 1995-10-25 Glaxo Group Ltd Medicaments
US5763576A (en) * 1995-10-06 1998-06-09 Georgia Tech Research Corp. Tetrapeptide α-ketoamides
TW442452B (en) 1996-03-01 2001-06-23 Akzo Nobel Nv Serine protease inhibitors having an alkynylamino side chain
US5633388A (en) * 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5736576A (en) * 1996-06-04 1998-04-07 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
WO1998007734A1 (en) 1996-08-21 1998-02-26 Hybridon, Inc. Oligonucleotide prodrugs
IT1285158B1 (en) 1996-09-17 1998-06-03 Angeletti P Ist Richerche Bio SOLUBLE POLYPEPTIDES WITH THE SERINO-PROTEASIS ACTIVITY OF NS3 OF THE HEPATITIS C VIRUS, AND PROCEDURE FOR THEIR PREPARATION AND
ATE229066T1 (en) 1996-09-24 2002-12-15 Procter & Gamble LIQUID DETERGENTS CONTAINING PROTEOLYTIC ENZYME, PEPTIDE ALDEHYDE AND A SOURCE OF BORIC ACID
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
EP0948523B1 (en) 1996-12-27 2004-03-17 Boehringer Ingelheim (Canada) Ltd. Peptidomimetic inhibitors of the human cytomegalovirus protease
WO1998037180A2 (en) 1997-02-22 1998-08-27 Abbott Laboratories Hcv fusion protease and polynucleotide encoding same
WO1999007733A2 (en) 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptides
GB9809664D0 (en) 1998-05-06 1998-07-01 Hoffmann La Roche a-Ketoamide derivatives
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6576613B1 (en) * 1998-07-24 2003-06-10 Corvas International, Inc. Title inhibitors of urokinase
AR022061A1 (en) * 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd INHIBITING PEPTIDES OF HEPATITIS C, A PHARMACEUTICAL COMPOSITION CONTAINING THEM, THE USE OF THE SAME TO PREPARE A PHARMACEUTICAL COMPOSITION, THE USE OF AN INTERMEDIATE PRODUCT FOR THE PREPARATION OF THESE PEPTIDES AND A PROCEDURE FOR THE PREPARATION OF ANOGRAPH .
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
AR029851A1 (en) * 2000-07-21 2003-07-16 Dendreon Corp NEW PEPTIDES AS INHIBITORS OF NS3-SERINA PROTEASA DEL VIRUS DE HEPATITIS C
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
IL153670A0 (en) * 2000-07-21 2003-07-06 Schering Corp Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
SV2003000617A (en) 2000-08-31 2003-01-13 Lilly Co Eli INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017679A1 (en) * 1996-10-18 1998-04-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
WO1999007734A2 (en) * 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
WO2000052032A1 (en) * 1999-03-03 2000-09-08 Dainippon Pharmaceutical Co., Ltd. Heterocyclic compounds, intermediates thereof and elastase inhibitors
EP1157998A1 (en) * 1999-03-03 2001-11-28 Dainippon Pharmaceutical Co., Ltd. Heterocyclic compounds, intermediates thereof and elastase inhibitors
WO2001040262A1 (en) * 1999-12-03 2001-06-07 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
WO2001074768A2 (en) * 2000-04-03 2001-10-11 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAN WEI ET AL: "alpha-Ketoamides, alpha-ketoesters and alpha-diketones as HCV NS3 protease inhibitors.", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 10, no. 8, 17 April 2000 (2000-04-17), pages 711 - 713, XP002199468, ISSN: 0960-894X *
LLINAS-BRUNET MONTSE ET AL: "Studies on the c-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease.", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 8, no. 19, 6 October 1998 (1998-10-06), pages 2719 - 2724, XP002199470, ISSN: 0960-894X *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427681B2 (en) 2000-12-21 2008-09-23 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7531536B2 (en) 2000-12-21 2009-05-12 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7557106B2 (en) 2002-06-20 2009-07-07 Vertex Pharmaceuticals Incorporated Substituted pyrimidines useful as protein kinase inhibitors
US7378422B2 (en) 2003-09-05 2008-05-27 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US8187874B2 (en) 2003-10-27 2012-05-29 Vertex Pharmaceuticals Incorporated Drug discovery method
US7528142B2 (en) 2005-11-03 2009-05-05 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US11851422B2 (en) 2021-07-09 2023-12-26 Aligos Therapeutics, Inc. Anti-viral compounds

Also Published As

Publication number Publication date
JP2009051860A (en) 2009-03-12
JP2013032389A (en) 2013-02-14
HU229997B1 (en) 2015-04-28
AR033985A1 (en) 2004-01-21
CY1112267T1 (en) 2015-12-09
US20060205672A1 (en) 2006-09-14
IL153670A0 (en) 2003-07-06
PL366063A1 (en) 2005-01-24
EP1385870A2 (en) 2004-02-04
SI1385870T1 (en) 2010-08-31
KR100904788B1 (en) 2009-06-25
ECSP034438A (en) 2003-03-10
SK288064B6 (en) 2013-04-03
RU2008126266A (en) 2010-01-10
USRE43298E1 (en) 2012-04-03
NZ523782A (en) 2005-10-28
CY2011020I1 (en) 2016-12-14
NO332329B1 (en) 2012-09-03
CA2410662C (en) 2012-09-18
AU2001276988B2 (en) 2007-01-25
EP1385870B1 (en) 2010-03-17
NO2013003I1 (en) 2013-03-04
CN102372764A (en) 2012-03-14
AR069373A2 (en) 2010-01-20
MY139078A (en) 2009-08-28
PT1385870E (en) 2010-06-07
RU2355700C2 (en) 2009-05-20
ZA200210312B (en) 2004-03-29
CY2011020I2 (en) 2016-12-14
JP5775505B2 (en) 2015-09-09
KR20030025277A (en) 2003-03-28
NO20030272D0 (en) 2003-01-20
CZ2003151A3 (en) 2003-05-14
TWI324611B (en) 2010-05-11
US7012066B2 (en) 2006-03-14
US20110117057A1 (en) 2011-05-19
MY143322A (en) 2011-04-15
ATE461207T1 (en) 2010-04-15
PL206255B1 (en) 2010-07-30
HK1058047A1 (en) 2004-04-30
US20030216325A1 (en) 2003-11-20
CN102206247A (en) 2011-10-05
JP4298289B2 (en) 2009-07-15
WO2002008244A2 (en) 2002-01-31
CZ303213B6 (en) 2012-05-23
KR100939155B1 (en) 2010-01-28
US20040254117A9 (en) 2004-12-16
LU91910I2 (en) 2012-02-02
HUP0401730A2 (en) 2004-12-28
RU2355700C9 (en) 2010-03-20
AU7698801A (en) 2002-02-05
DE60141608D1 (en) 2010-04-29
IL153670A (en) 2012-06-28
DE122012000004I1 (en) 2012-04-26
BR0112540A (en) 2003-06-24
DK1385870T3 (en) 2010-07-05
MXPA03000627A (en) 2004-07-30
NO2013003I2 (en) 2017-01-16
JP2004504404A (en) 2004-02-12
HUP0401730A3 (en) 2012-09-28
NO20030272L (en) 2003-03-21
SK752003A3 (en) 2003-08-05
CN1498224A (en) 2004-05-19
CN102206247B (en) 2013-03-27
ES2341534T3 (en) 2010-06-22
KR20090030330A (en) 2009-03-24
CA2410662A1 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
WO2002008244A3 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
WO2002008256A3 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
WO2003062265A3 (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
WO2002008198A3 (en) Novel imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus
MXPA03000626A (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus.
TWI265927B (en) Novel compounds as NS3-serine protease inhibitors of hepatitis C virus
WO2002008251A3 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
WO2001081325A3 (en) Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties
WO2005087725A3 (en) Novel compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2005087721A3 (en) Compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2001077113A3 (en) Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
WO2005087731A8 (en) Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2005051980A8 (en) Depeptidized inhibitors of hepatitis c virus ns3 protease
WO2001074768A3 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
WO2008124148A3 (en) Sulfur compounds as inhiibitors of hepatitis c virus ns3 serine protease
NO20063205L (en) Inhibitors of hepatitis C virus NS3 / NS4A serine protease
ATE513844T1 (en) ACYLSULFONAMIDE COMPOUNDS AS INHIBITORS OF THE NS3 SERINE PROTEASE OF THE HEPATITIS C VIRUS
WO2007008657A3 (en) Hepatitis c virus inhibitors
WO2002048116A3 (en) Inhibitors of hepatitis c virus ns3 protease
WO2004032827A3 (en) Hepatitis c virus inhibitors
WO2002060926A3 (en) Hepatitis c tripeptide inhibitors
WO2004002940A8 (en) Inhibitors of hcv ns5b polymerase
WO2004043383A8 (en) A new target for angiogenesis and anti-angiogenesis therapy
WO2010021717A3 (en) Hcv protease inhibitors
MX2010004704A (en) Macrocyclic inhibitors of hepatitis c virus ns3 serine protease.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EC EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2410662

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001276988

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001954764

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002/10312

Country of ref document: ZA

Ref document number: 200210312

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 153670

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 89/CHENP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PV2003-151

Country of ref document: CZ

Ref document number: 1020037000784

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/000627

Country of ref document: MX

Ref document number: 752003

Country of ref document: SK

Ref document number: 018131115

Country of ref document: CN

Ref document number: 03003340

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 523782

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2003105217

Country of ref document: RU

Kind code of ref document: A

Ref country code: RU

Ref document number: RU A

WWP Wipo information: published in national office

Ref document number: 1020037000784

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2003-151

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2001954764

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 523782

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 523782

Country of ref document: NZ